Invest and Sell Abridge Stock

Abridge Stock Price

Forge Price ¹

Price not yet available

Last Closed Trade ²

Close Date

xx/xx/xx

Last Closed Trade Price

$xx.xx

Last Funding Round (LFR)

Date

xx/xx/xx

Price per Share

$xx.xx

Access Stock Price

Abridge Funding Rounds and Valuation

Funding History Chart

Funding Round Details

	Funding Date	Share Class	Amount Raised	Price per Share	Post-Money Valuation	Key Investors
	02/17/2025	Series D	$250MM	$xx.xx	$2.75B	Bessemer Venture Partners, California Health Care Foundation, Capitalg, Cvs Health Ventures, Elad Gil, Ivp, K. Ventures, Lightspeed Venture Partners, Nvidia, Redpoint Ventures, Spark Capital, Sv Angel
Price per Share $xx.xx Shares Outstanding 2,777,466 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Bessemer Venture Partners, California Health Care Foundation, Capitalg, Cvs Health Ventures, Elad Gil, Ivp, K. Ventures, Lightspeed Venture Partners, Nvidia, Redpoint Ventures, Spark Capital, Sv Angel
	02/23/2024	Series C	$150MM	$xx.xx	$850MM	Bessemer Venture Partners, Cvs Health Ventures, Ivp, Kaiser Permanente Ventures, Lightspeed Venture Partners, Mass General Brigham, Redpoint Ventures, Spark Capital, Union Square Ventures, Wittington Ventures
Price per Share $xx.xx Shares Outstanding 4,527,706 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Bessemer Venture Partners, Cvs Health Ventures, Ivp, Kaiser Permanente Ventures, Lightspeed Venture Partners, Mass General Brigham, Redpoint Ventures, Spark Capital, Union Square Ventures, Wittington Ventures
	10/26/2023	Series B	$30MM	$xx.xx	$232.25MM	American College Of Cardiology, Bessemer Venture Partners, Cvs Health Ventures, Kaiser Permanente Ventures, Lifepoint Health, Mayo Clinic, Scan Group, Spark Capital, Uc Investments
Price per Share $xx.xx Shares Outstanding 2,735,903 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors American College Of Cardiology, Bessemer Venture Partners, Cvs Health Ventures, Kaiser Permanente Ventures, Lifepoint Health, Mayo Clinic, Scan Group, Spark Capital, Uc Investments
	08/11/2022	Series A-1	$12.5MM	$xx.xx	$144.48MM	Bessemer Venture Partners, Pillar Vc, Union Square Ventures, Upmc Enterprises, Whistler Capital, Wittington Ventures, Yoshua Bengio
Price per Share $xx.xx Shares Outstanding 1,417,893 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Bessemer Venture Partners, Pillar Vc, Union Square Ventures, Upmc Enterprises, Whistler Capital, Wittington Ventures, Yoshua Bengio
	10/06/2020	Series A	$10.16MM	$xx.xx	$102.98MM	Aneesh Chopra, Bessemer Venture Partners, Esther Dyson, Kdt Ventures, Pillar Vc, Union Square Ventures, Upmc Enterprises, Zen Chu
Price per Share $xx.xx Shares Outstanding 2,130,677 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Aneesh Chopra, Bessemer Venture Partners, Esther Dyson, Kdt Ventures, Pillar Vc, Union Square Ventures, Upmc Enterprises, Zen Chu
	02/14/2019	Series Seed	$5.32MM	$xx.xx	$26.59MM	Kdt Ventures, Pillar Vc
Price per Share $xx.xx Shares Outstanding 2,187,596 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Kdt Ventures, Pillar Vc

Access Stock Price

Abridge Stock FAQs

To buy and sell Abridge stock

Can you buy Abridge stock?

As Abridge is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Abridge, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

How to buy Abridge stock?

To invest in a private company like Abridge through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Abridge stock?

Yes, you may sell the Abridge stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Abridge stock?

If you hold private company shares of Abridge – whether as an employee or an early investor – Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Abridge on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

To learn more about Abridge stock

Is Abridge a public company?

No, Abridge is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Abridge’s stock price?

Abridge is a privately held company and therefore does not have a public stock price. However, you may access Abridge private market stock price with Forge Data.

What is Abridge’s stock ticker symbol?

Abridge does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Leadership & Board

Leadership

Shivdev Rao MD

Co-Founder & Chief Executive Officer

Julia Chapin

Chief Operating Officer

Sandeep Konam

Co-Founder & Chief Technology Officer

Zachary Lipton Ph.D

Chief Technology Officer, Chief Science Officer & Scientific Advisor

Tina Shah

Chief Clinical Officer

Brian Wilson

Chief Commercial Officer

Lindsey Spellman

Head of Marketing

Board

Andrew Weissman JD

Union Square Ventures

Abridge News and Media Highlights

FinSMEs 02/17/2025

Abridge Raises $250M in Series D Funding

Abridge, San Francisco, CA-based provider of a generative AI platform for clinical conversations, raised $250M in Series D funding.

FierceHealthcare 02/23/2024

Abridge clinches $150M to build out generative AI for medical documentation

Investors continue to pour money into generative AI startups, and Abridge is riding this wave as it rapidly scales its technology across U.S. health systems. The Pittsburgh-based startup banked a hefty $150 million series C funding round to invest in more research and development to build bedrock foundation models to power both improvements to the company's existing technology and new products, CEO Shivdev Rao, M.D., told Fierce Healthcare.

Reuters 02/23/2024

Healthcare startup Abridge raises $150 mln for AI model for clinicians

Abridge, a startup building artificial intelligence-powered clinical documentation tools, has raised $150 million in a Series C round, the company told Reuters, as more investors seek exposure to industry-specific generative AI applications. The funding, led by Lightspeed Venture Partners and Redpoint Ventures, valued Abridge at about $850 million. The company last raised funds just four months ago and was then valued at over $200 million, according to PitchBook data.

FierceHealthcare 10/26/2023

CVS, Mayo Clinic, Spark Capital back Abridge's $30M round to scale up generative AI-powered notetaking for doctors

Abridge launched in 2018 and uses AI to increase the speed and accuracy of medical note-taking, leveraging a proprietary dataset derived from more than 1.5 million medical encounters. Around 5,000 doctors currently use the company's software, which automatically converts a patient-clinician conversation into a structured clinical note draft in real-time. The company banked $30 million in a series B raise to support large-scale health system rollouts of its technology and accelerate product advances that will create additional value for patients, clinicians and health systems, the company said.

Other Companies Like Abridge in the Healthcare software Sector

Sector: Healthcare

Subsector: Healthcare software

					Last Funding Round
Company		Forge Price	Forge Price Change ⁵	Last Closed Trade	Share Class	Post-Money Valuation	Price per Share	Amount Raised
	Ambience Healthcare	--	--	$xx.xx	--	--	--	--
	Benchling	--	--	$xx.xx	Series F	$6.1B	$xx.xx	$95MM
	Cedar	--	--	$xx.xx	Series D	$3.19B	$xx.xx	$255MM
	Hippocratic AI	--	--	$xx.xx	Series B	$1.64B	$xx.xx	$141MM
	Huma	--	--	$xx.xx	Series D-1	$731.49MM	$xx.xx	$20.25MM
	Incredible Health	--	--	$xx.xx	Series B	$1.65B	$xx.xx	$80MM
	Innovaccer	$7.39	+146.33%	$xx.xx	Series F-1	$3.88B	$xx.xx	$153.04MM
	Insilico Medicine	--	--	$xx.xx	--	--	--	--
	OpenEvidence	--	--	$xx.xx	Series A	$1B	$xx.xx	$75MM
	TigerConnect	--	--	$xx.xx	Series D-1	$366.32MM	$xx.xx	$41.5MM

See All Companies

Updated on: Feb 21, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.

Abridge Stock